Financial Performance - Revenue for Q3 2024 was CNY 172,191,555.13, a decrease of 1.40% year-over-year[3] - Net profit attributable to shareholders was CNY 4,087,519.85, down 54.45% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was CNY 5,268,576.05, a decline of 30.65% year-over-year[3] - Basic earnings per share for Q3 2024 was CNY 0.0414, a decrease of 52.58% from the previous year[3] - Total operating revenue for Q3 2024 was CNY 560,341,100.40, a decrease of 1.0% from CNY 569,885,071.76 in the same period last year[16] - Net profit for Q3 2024 was CNY 22,021,962.58, a significant decline of 69.8% compared to CNY 72,934,990.11 in Q3 2023[16] - Basic earnings per share decreased to CNY 0.2183 from CNY 0.7089 in the previous year, reflecting a drop of 69.1%[17] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,422,894,551.73, an increase of 6.38% from the end of the previous year[3] - Total assets increased to CNY 1,422,894,551.73, up 6.4% from CNY 1,337,497,679.93 at the end of the previous year[15] - Total liabilities rose to CNY 400,930,413.44, an increase of 70.9% compared to CNY 234,311,773.52 in the same period last year[15] - Shareholders' equity attributable to the parent company was CNY 1,021,964,138.29, down 7.36% from the previous year[3] - The company's total equity decreased to CNY 1,021,964,138.29, down 7.4% from CNY 1,103,185,906.41 year-over-year[15] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 71,464,477.74, an increase of 42.25% compared to the same period last year[7] - Operating cash inflow for the period was CNY 567,084,978.47, an increase of 3.8% compared to CNY 547,985,308.34 in the previous period[18] - Net cash outflow from operating activities was CNY 495,620,500.73, slightly decreased from CNY 497,747,218.30 in the previous period[19] - Net cash flow from operating activities was CNY 71,464,477.74, up 42.2% from CNY 50,238,090.04 in the previous period[19] - Cash inflow from financing activities was CNY 241,800,000, with a net cash flow of CNY 71,632,248.40, reversing from a net outflow in the previous period[19] - The ending cash and cash equivalents balance was CNY 365,428,864.02, an increase from CNY 324,470,029.93 in the previous period[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,527[8] - The top ten shareholders held a combined 28.90% of shares, with Chengdu Enwei Investment (Group) Co., Ltd. holding 29,733,200 shares[8] - The company has a total of 67.83% of shares controlled by a group of shareholders acting in concert, indicating a strong ownership structure[9] - The top ten shareholders include several investment partnerships, with the largest holding being 1,264,912 shares, representing 1.23% of total shares[11] - The company has not reported any changes in the number of preferred shareholders or significant changes in restricted shares[12] Expenses - Total operating costs increased to CNY 534,869,746.20, up 7.5% from CNY 497,376,667.73 year-over-year[16] - Research and development expenses were CNY 5,770,697.03, a decrease of 61.4% from CNY 14,966,254.02 in the previous year[16] - Sales expenses increased to CNY 187,705,109.10, up 17.8% from CNY 159,371,926.26 year-over-year[16] - The company reported a significant increase in tax expenses to CNY 9,447,037.16, compared to CNY 7,600,231.62 in the same period last year[16] Asset Changes - The company reported a significant increase in construction in progress by 303.77% to CNY 35,605,470.48 due to increased investment in fundraising projects[7] - The company's cash and cash equivalents increased to ¥366,010,905.68 from ¥236,120,514.71, representing a growth of approximately 55.0%[13] - Accounts receivable rose to ¥104,098,324.83 from ¥93,095,689.67, indicating an increase of about 11.5%[13] - The total current assets reached ¥864,538,310.27, up from ¥786,859,452.41, reflecting a growth of approximately 9.8%[13] - Long-term equity investments decreased to ¥330,447.34 from ¥373,989.35, showing a decline of about 11.6%[13] - The company's fixed assets decreased to ¥209,539,965.27 from ¥220,638,376.27, a reduction of approximately 5.0%[13] - The company's intangible assets decreased to ¥137,396,425.04 from ¥148,043,809.24, representing a decline of about 7.2%[13] - The company reported a significant increase in prepayments, rising to ¥25,311,174.63 from ¥14,911,422.66, which is an increase of approximately 69.5%[13] - Cash paid for purchasing fixed assets and other long-term assets was CNY 46,088,085.94, significantly higher than CNY 15,592,083.55 in the previous period[19] - Cash paid for employee compensation was CNY 148,781,353.45, slightly increased from CNY 147,909,484.90 in the previous period[19] - Cash paid for taxes was CNY 60,845,460.61, down from CNY 65,284,660.61 in the previous period[19]
恩威医药(301331) - 2024 Q3 - 季度财报